Printer Friendly

CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE

 CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM
 SIGN VACCINE ALLIANCE
 WORCESTER, Mass., and PHILADELPHIA, Sept. 14 /PRNewswire/ -- Cambridge, Biotech Corporation (NASDAQ: CBCX) and SmithKline Beecham (NYSE: SBH) today announced they have signed a definitive agreement for SmithKline Beecham today announced they have signed an definitive agreement for SmithKline Beecham to use CBC's proprietary QS-21 Stimulon(tm) adjuvant in a number of vaccines. CBC's adjuvant is a potent immune system stimulant that has been demonstrated to enhance protective immune responses to vaccinations.
 Under the agreement, SmithKline Beecham will use CBC's QS-21 Stimulon adjuvant in potentially over 25 new generation vaccines. SmithKline Beecham has paid an initial licensing fee and will make additional license fee payments over the next several years to CBC. In addition, SmithKline Beecham will purchase from CBC the bulk adjuvant for formulation with vaccines and will also pay royalties on any sales of vaccines containing CBC's adjuvant.
 "We are delighted to have SmithKline Beecham as one of our significant partners on a broad range of vaccines," said Patrick J. Leonard, president and CEO of Cambridge Biotech Corporation. SmithKline Beecham has taken a number of steps to increase its presence in the global vaccine arena and its share of the worldwide vaccine market is growing steadily."
 "This agreement is another step in SmithKline Beecham's strategy for leadership in the development of a new generation of vaccines," said Jan Leschly, chairman of SmithKline Beecham's pharmaceuticals business. "The ability to target specific immune responses is an important aspect of our work. Cambridge Biotech's pioneering effort in adjuvant development will complement our new vaccine development program for several viral hepatitis diseases, Lyme Disease, herpes and influenza." Adjuvant Background
 CBC has conducted extensive research on a family of purified saponin compounds derived from the soapbark tree Quillaja saponaria, found in South America and Hindustan and cultivated in large commercial scale, producing crude saponin products for applications as varied as heavy industrial cleaners, food emulsifiers and cosmetic additives, among other applications. CBC's family of purified saponin compounds has been issued a patent under the trade name Stimulon adjuvant. The compound QS-21 comprises CBC's current adjuvant.
 Among the reported effects if the Stimulon adjuvant are potent stimulation of antibody responses to proteins, including recombinant DNA proteins, and induction of immunological memory. Unlike other adjuvants, the Stimulon adjuvant not only elicits a humoral response, but also a cell-mediated immunity. In effect, the Stimulon adjuvant elicits the production of targeted cytotoxic (killer) T-Cells, or CTLs, even when used with soluble recombinant DNA subunit vaccines. Stimulon is currently being evaluated as an adjunct to immunotherapy against malignant melanoma by the Memorial Sloan-Kettering Cancer Center.
 Cambridge Biotech Corporation, is a leading diagnostics and therapeutics company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal vaccines and pharmaceuticals, over-the-counter medicines, and clinical laboratory testing services.
 -0- 9/14/92 R
 /CONTACT: Sharyn M. Arnold of SmithKline Beecham, 215-751-7074, or Peter P. Hartman of Cambridge Biotech Corporation, 508-797-5777/
 (CBCX SBH) CO: SmithKline Beecham; Cambridge Biotech Corporation ST: Massachusetts, Pennsylvania IN: MTC SU: CON


TM -- NE005R -- 9148 09/14/92 12:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 14, 1992
Words:534
Previous Article:SCHERER ANNOUNCES A SECONDARY OFFERING AND FILES A REGISTRATION STATEMENT
Next Article:CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
Topics:


Related Articles
MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
RIBI IMMUNOCHEM EXPANDS COMMERCIAL RELATIONSHIP WITH SMITHKLINE BEECHAM BY PROVIDING ADJUVANTS FOR IMPORTANT GROUP OF BACTERIAL VACCINES
SMITHKLINE BEECHAM ANNOUNCES PEDIATRIC VACCINE AGREEMENT WITH MEDEVA
SMITHKLINE BEECHAM TO INTRODUCE HAVRIX, HEPATITIS A VACCINE, IN THE PEOPLE'S REPUBLIC OF CHINA
SMITHKLINE BEECHAM ANNOUNCES REGISTRATION IN CHINA OF HAVRIX, THE WORLD'S FIRST HEPATITIS A VACCINE
SMITHKLINE BEECHAM AND VIRUS RESEARCH INSTITUTE ANNOUNCE COLLABORATION FOR MICROBIAL RESEARCH
TULANE UNIVERSITY AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
SMITHKLINE BEECHAM ENTERS RESEARCH COLLABORATIONS IN CHINA; NEXT STEP IN EXPANDING PRESENCE IN CHINESE HEALTHCARE
SmithKline Beecham Announces New Drug Discovery Collaborations

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters